• Strategic SERCA Inhibition with BHQ: A New Era for Stem Cell

  2026-05-14

  This article explores how 2,5-di-tert-butylbenzene-1,4-diol (BHQ), a selective SERCA inhibitor, is redefining calcium signaling research and stem cell mobilization. Integrating mechanistic insights from recent studies, including Li et al. (2025), we provide translational researchers with actionable protocol guidance, competitive context, and a forward-looking vision for regenerative medicine. This piece synthesizes evidence from peer-reviewed literature and curated content assets to chart a new strategic pathway for BHQ in clinical and preclinical workflows, while highlighting APExBIO's leadership in compound quality and workflow support.

• Syringin Enhances Sunitinib Efficacy in RCC via EGFR/PI3K/Ak

  2026-05-13

  This study demonstrates that Syringin, a natural product, inhibits renal cell carcinoma (RCC) cell proliferation and enhances apoptosis by targeting the EGFR/PI3K/Akt signaling pathway. Notably, Syringin significantly increases RCC sensitivity to sunitinib, providing a mechanistically validated approach to overcoming drug resistance in RCC therapy.

• Coumestrol Triggers Ferroptosis in RA-FLS via PMAIP1 Stabili

  2026-05-13

  This study reveals that Coumestrol, a phytoestrogen estrogen receptor antagonist, suppresses proliferation and inflammation in rheumatoid arthritis fibroblast-like synoviocytes by inducing ferroptosis through stabilization of mitochondrial PMAIP1. The findings highlight a novel cell death-mediated approach for modulating RA synovial pathology and suggest new experimental avenues for researchers.

• AI-Driven Discovery of Senolytics: Advances and Research Too

  2026-05-12

  This article reviews a key study that used machine learning to identify novel senolytic compounds, highlighting methodological advances and their significance for targeted cell elimination in disease contexts. The findings underscore the potential for AI to accelerate early-stage drug discovery and detail how these approaches can complement preclinical cancer and senescence research.

• Erlotinib (NSC 718781): Integrative Analysis of EGFR Inhibit

  2026-05-12

  Explore how Erlotinib (NSC 718781) enables advanced EGFR signaling inhibition and reveals new strategies against SCUBE3-mediated resistance in cancer research. This article offers unique, practical guidance for scientists seeking to overcome therapy resistance beyond conventional assay protocols.

• Estradiol–Autophagy Axis: Multi-Organ Protection in Perimeno

  2026-05-11

  This study establishes that declining estradiol levels during perimenopause are linked to increased cardiometabolic and renal risk, and demonstrates that estrogen’s protective effects are mediated by receptor-driven autophagy. Integrating human cohort data, network pharmacology, and mouse models, the research provides mechanistic insights crucial for designing precision hormone therapies.

• Gefitinib (ZD1839): Precision EGFR Inhibition in Assembloid

  2026-05-11

  Unlock the full potential of Gefitinib (ZD1839) for dissecting EGFR signaling and resistance in advanced tumor assembloid models. This guide delivers actionable protocols, troubleshooting insights, and key innovations for researchers seeking robust, physiologically relevant cancer workflows.

• ARCA EGFP mRNA: Direct-Detection Reporter for Mammalian Cell

  2026-05-10

  ARCA EGFP mRNA enables robust, quantitative fluorescence-based transfection assays in mammalian cells. This direct-detection reporter features co-transcriptional ARCA capping for enhanced mRNA stability and translation efficiency. Researchers achieve >90% transfection efficiency in HEK293T cells using this product as a control.

• Biotin-tyramide: Mechanistic Leverage for Translational Disc

  2026-05-09

  This thought-leadership article explores how Biotin-tyramide (A8011, APExBIO) is redefining enzyme-mediated signal amplification in translational research. Integrating mechanistic clarity, strategic guidance, and recent advances in proximity labeling, we provide a roadmap for researchers to achieve ultra-sensitive, spatially resolved biomolecule detection and functional mapping in complex tissues. This piece critiques the status quo, delivers actionable protocol parameters, and outlines implications for next-generation spatial biology applications.

• ATRA Reverses Chemotherapy-Induced PARPi Resistance in EOC

  2026-05-08

  This study demonstrates that all-trans retinoic acid (ATRA) can re-sensitize epithelial ovarian cancer (EOC) cells to PARP inhibitors after cisplatin-induced resistance. By targeting a metabolic gene signature including NAMPT and reducing intracellular NAD+ levels, ATRA offers a promising adjunct to maintenance therapy, with broad implications for overcoming drug resistance in EOC.

• BMS-777607: c-Met Inhibitor Applications in Cancer & Platele

  2026-05-08

  BMS-777607 stands out as a selective c-Met inhibitor, bridging cancer metastasis modeling and optimized stem cell-derived platelet production. This guide translates advanced research into actionable workflows, protocol parameters, and troubleshooting tips for reproducible MET pathway inhibition.

• Imipramine in Bench Research: Advanced Protocols & Autophagy

  2026-05-07

  Imipramine, a classic tricyclic antidepressant, is now an indispensable tool for dissecting autophagy, apoptosis, and tumor biology in cellular models. This article delivers actionable workflows, troubleshooting strategies, and integrates cutting-edge lipidomic insights to maximize research impact across oncology, neuroscience, and immunology.

• Applied Workflows with Everolimus (RAD001) for Cancer Resear

  2026-05-07

  Everolimus (RAD001) offers precision control over mTOR signaling, unlocking robust cancer cell proliferation inhibition and advanced apoptosis assays. This guide translates recent in vitro methodology breakthroughs into actionable protocols, troubleshooting insights, and model-specific tips for translational oncology teams.

• Mechanisms of Hepatocyte Death in Liver Disease: Clinical In

  2026-05-06

  The reference study by Luedde et al. provides a comprehensive review of how distinct cell death pathways—apoptosis, necrosis, and necroptosis—govern the initiation and progression of liver diseases, including fibrosis and cancer. By detailing molecular mechanisms and clinical correlations, the paper emphasizes the importance of targeting cell death responses for improved diagnosis and therapy in hepatic pathology.

• EZ Cap™ Firefly Luciferase mRNA: Next-Gen Reporter for Preci

  2026-05-06

  Discover how EZ Cap™ Firefly Luciferase mRNA enables robust, reproducible gene regulation and in vivo imaging. This article reveals its unique Cap 1 design and bioluminescence mechanism, offering deeper scientific insight and practical assay guidance.

15777 records 1/1052 page Next 12345 下5页 Last page